Heteroaryl allosteric modulators of nicotinic acetylcholine receptors

1. A compound having the formula I:

or a pharmaceutically acceptable salt thereof, wherein:

Y is selected from

X is selected from

G 1 is CR 9 , or N;

G 2 is CR 9 , or N;

G 3 is CR 9 , or N;

G 4 is is CR 9 , or N;

provided that at least one of G 1 -G 4 is N and at least two of G 1 -G 4 are CR 9 ;

G 5 is CR 9 , or N;

G 6 is O, or S;

G 7 is CR 9 , or N;

A is heteroaryl which is optionally substituted with 1 to 4 R groups each independently selected from OH, oxo, amino, amido, carboxyl, keto, cyano, alkoxy, S(O) m -alkyl, halogen, aminoalkyl, hydroxyalkyl, alkyl, cycloalkyl, alkynyl, aryl, heteroaryl, and heterocyclyl, wherein said amino, amido, carboxyl, keto, alkoxy, S(O) m -alkyl, aminoalkyl, hydroxyalkyl, alkyl, cycloalkyl, alkynyl, aryl, heteroaryl and heterocyclyl are optionally substituted with one or more substituents independently selected from halogen, OH, oxo, CF 3 , OCF 3 , CN, (C 1 -C 6 )alkyl, O(C 1 -C 4 )alkyl, S(O) m -(C 1 -C 4 )alkyl, C═O(C 1 -C 4 )alkyl, (C═O)NR 7 R 8 , (C═O)OR 7 , (C 2 -C 4 )alkynyl, (C 3 -C 6 )cycloalkyl, O(C 3 -C 6 )cycloalkyl, C═O(C 3 -C 6 )cycloalkyl, aryl, heteroaryl and heterocyclyl, wherein said alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl are optionally independently substituted with one or more halogen, CF 3 , OH and oxo;

R 1 is H or (C 1 -C 4 )alkyl;

R 2 is H or (C 1 -C 4 )alkyl;

R 3 is H, halogen, (C 1 -C 4 )alkyl, wherein said alkyl is optionally substituted with one or more halogen;

R 4 is H, halogen or (C 1 -C 4 )alkyl, wherein said alkyl is optionally substituted with one or more halogen;

or, R 3 and R 4 optionally can come to together to form a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl ring wherein said ring may be optionally substituted with one or more substituents independently selected from OH, halogen, or (C 1 -C 4 )alkyl;

R 5 is H or (C 1 -C 4 )alkyl;

R 6 is H or (C 1 -C 4 )alkyl;

R 7 and R 8 are independently selected from H, (C 1 -C 6 )alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl, wherein said alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl are optionally substituted with one or more substituents independently selected from halogen, OH, CF 3, (C 1 -C 4 )alkyl, O(C 1 -C 4 )alkyl, cycloalkyl, CN, aryl, heteroaryl, and heterocyclyl, wherein said alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl are optionally substituted with one or more substituents independently selected from halogen, OH, CF 3 , (C 1 -C 4 )alkyl, O(C 1 -C 4 )alkyl, and CN;

R 9 is H or (C 1 -C 4 )alkyl;

R a is H or (C 1 -C 4 )alkyl;

R b is H or (C 1 -C 4 )alkyl; and

m is 0, 1, or 2.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is

3. The compound according to claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 9 is H or methyl.

4. The compound according to claim 3 , or a pharmaceutically acceptable salt thereof, wherein A is heteroaryl which is optionally substituted with 1 to 3 R groups independently selected from halogen, CN, (C 1 -C 6 )alkyl, O(C 1 -C 6 )alkyl, NR 7 R 8 , (C 3 -C 6 )cycloalkyl, aryl, heteroaryl and heterocyclyl, wherein said alkyl, NR 7 R 8 , (C 3 -C 6 )cycloalkyl, aryl, heteroaryl and heterocyclyl are optionally substituted with one or more substituents independently selected from halogen, CN, (C 1 -C 4 )alkyl, (C═O)O(C 1 -C 4 )alkyl and phenyl, wherein said alkyl is optionally substituted with one or more halogen.

5. The compound according to claim 4 , or a pharmaceutically acceptable salt thereof, wherein R 5 , R 6 , R a and R b are independently H or methyl.

6. The compound according to claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 are independently H, F, or methyl.

7. The compound according to claim 6 , or a pharmaceutically acceptable salt thereof, wherein R 7 and R 8 are independently selected from H, (C 1 -C 6 )alkyl, cyclopentyl and phenyl wherein said alkyl and phenyl are optionally substituted with halogen or phenyl.

8. The compound of claim 1 having the formula:

or a pharmaceutically acceptable salt thereof, wherein:

Y is selected from

X is

A is selected from oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, isoxazolyl, benzoxazolyl, isothiazolyl, triazolyl, pyrazolyl, quinazolinyl, oxazolopyridinyl, quinoxalinyl, imidazopyridazinyl, benzothiazolyl, naphthyridinyl, pyrazolopyridinyl, cinnolinyl, isoquinolyl, thienopyridinyl, indazolyl, furopyridinyl, pyridinyl, pyrimidinyl, pyridazinyl and pyrazinyl each optionally substituted with 1-2 R groups independently selected from (C 1 -C 6 )alkyl, O(C 1 -C 6 )alkyl, NR 7 R 8 , (C 3 -C 6 )cycloalkyl, aryl, heteroaryl and heterocyclyl, wherein each are optionally substituted with one or more substituents independently selected from halogen, CF 3 , CN, (C 1 -C 4 )alkyl, O(C 1 -C 6 )alkyl, (C═O)O(C 1 -C 4 )alkyl and phenyl;

R 3 is H or methyl;

R 4 is H or methyl;

R 5 is H or methyl;

R 6 is H or methyl;

R 7 and R 8 are independently selected from H, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, aryl, heteroaryl and heterocyclyl; and

R 9 is independently H or methyl.

9. The compound of claim 8 having the formula I, or a pharmaceutically acceptable salt thereof, wherein;

Y is selected from

X is

A is selected from oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, isoxazolyl, and benzoxazolyl, each optionally substituted with 1 R group selected from (C 1 -C 6 )alkyl, O(C 1 -C 6 )alkyl, NR 7 R 8 , (C 3 -C 6 )cycloalkyl, phenyl, pyridinyl, morpholinyl, imidazolyl, pyrazolyl, oxadiazolyl, pyrrolidinyl, piperazinyl, triazolyl and tetrahydropyranyl wherein each are optionally substituted with one or more substituents independently selected from halogen, CF 3 , CN, (C 1 -C 4 )alkyl, O(C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C═O)O(C 1 -C 4 )alkyl and phenyl;

R 3 is H or methyl;

R 4 is H or methyl;

R 5 is H or methyl;

R 6 is H or methyl;

R 7 and R 8 are independently selected from H, (C 1 -C 6 )alkyl, cyclopentyl and phenyl, wherein each alkyl, cyclopentyl, and phenyl are optionally substituted with one or more substituents independently selected from halogen and phenyl; and

R 9 is H or methyl.

10. The compound of claim 1 which is selected from the group consisting of

5-[trans-3-(1,3-Benzoxazol-2-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide;

5-{trans-3-[5-(2,4-Difluorophenyl)-1,3,4-thiadiazol-2-yl]-2,2-dimethylcyclopropyl}pyridine-2-sulfonamide;

5-[(1S,3S)-2,2-Dimethyl-3-(3-phenyl-1,2,4-oxadiazol-5-yl)cyclopropyl]pyridine-2-sulfonamide;

5-[trans-2-(3-Phenyl-1,2,4-oxadiazol-5-yl)cyclopropyl]pyridine-2-sulfonamide;

6-Methyl-5-[trans-2-(3-phenyl-1,2,4-oxadiazol-5-yl)cyclopropyl]pyridine-2-sulfonamide;

2-[(1S,3S)-2,2-Dimethyl-3-(3-phenyl-1,2,4-oxadiazol-5-yl)cyclopropyl]-1,3-thiazole-5-sulfonamide;

5-[(1R,3R)-3-(3-Cyclohexyl-1,2,4-oxadiazol-5-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide;

5-[(1S,3S)-2,2-Dimethyl-3-(5-phenyl-1,3-oxazol-2-yl)cyclopropyl]pyridine-2-sulfonamide;

5-[(1R,3R)-3-(5-Cyclopentyl-1,3-thiazol-2-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide;

6-[(1S,3S)-3-(3-Cyclohexyl-1,2,4-oxadiazol-5-yl)-2,2-dimethylcyclopropyl]pyridine-3-sulfonamide;

5-[trans-2,2-Dimethyl-3-(5-phenyl-1,2,4-oxadiazol-3-yl)cyclopropyl]pyridine-2-sulfonamide;

5-[trans-3-(3-Cyclopentylisoxazol-5-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide;

5-{trans-3-[5-(3-Fluorophenyl)isoxazol-3-yl]-2,2-dimethylcyclopropyl}pyridine-2-sulfonamide;

5-[(1R,3R)-2,2-Dimethyl-3-(3-phenyl-1,2,4-oxadiazol-5-yl)cyclopropyl]pyridine-2-sulfonamide;

5-[(1R,3R)-2,2-Dimethyl-3-{[5-(trifluoromethyl)pyridin-3-yl]-1,2,4-oxadiazol-5-yl}cyclopropyl]pyridine-2-sulfonamide;

5-[(1R,3R)-3-(3-Cyclopentyl-1,2,4-oxadiazol-5-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide;

5-[(1R,3R)-3-(5-Cyclopentyl-1,3-oxazol-2-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide;

5-[(1R,3R)-2,2-Dimethyl-3-(5-phenyl-1,3-thiazol-2-yl)cyclopropyl]pyridine-2-sulfonamide;

5-{(1R,3R)-3-[3-(5-Chloro-2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-2-sulfonamide;

5-{(1R,3R)-3-[3-(3-Fluorophenyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-2-sulfonamide;

5-{(1R,3R)-3-[3-(2,4-Difluorophenyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-2-sulfonamide;

5-{(1R,3R)-3-[3-(5-Fluoropyridin-3-yl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-2-sulfonamide;

5-[(1R,3R)-2,2-Dimethyl-3-{3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}cyclopropyl]pyridine-2-sulfonamide;

5-{(1R,3R)-3-[3-(3,3-Difluorocyclobutyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-2-sulfonamide;

5-[(1R,3R)-3-(3-Cyclobutyl-1,2,4-oxadiazol-5-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide;

5-{(1R,3R)--[3-(Cyclopropylmethyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-2-sulfonamide;

5-{(1R,3R)-2,2-Dimethyl-3[3-(propan-2-yl)-1,2,4-oxadiazol-5-yl]cyclopropyl}pyridine-2-sulfonamide;

5-[(1R,3R)-2,2-Dimethyl-3-(5-phenyl-1,3-oxazol-2-yl)cyclopropyl]pyridine-2-sulfonamide;

5-{(1S,3S)-3-[3-(3-Fluorophenyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-2-sulfonamide;

5-{(1S,3S)-3[3-(5-Chloro-2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-2-sulfonamide;

5-{(1S,3S)-3[3-(2,4-Difluorophenyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-2-sulfonamide;

5-[(1S,3S)-2,2-Dimethyl-3-{3-[5-(trifluoromethyl)pyridin-3-yl]-1,2,4-oxadiazol-5-yl}cyclopropyl]pyridine-2-sulfonamide;

5-[(1S,3S)-2,2-Dimethyl-3-{3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}cyclopropyl]pyridine-2-sulfonamide;

5-[(1S,3S)-3-(3-Cyclohexyl-1,2,4-oxadiazol-5-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide;

5-[(1S,3S)-3-(3-Cyclopentyl-1,2,4-oxadiazol-5-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide;

5-{(1S,3S)-3-[3-(3,3-Difluorocyclobutyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-2-sulfonamide;

5-[(1S,3S)-3 -(3-Cyclobutyl- 1,2,4-oxadiazol-5-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide;

5-{(1S,3S)-3-[3(Cyclopropylmethyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-2-sulfonamide;

5-[(1S,3S)-3-(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide;

5-[(1S,3S)-3-(3-tert-Butyl-1,2,4-oxadiazol-5-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide;

5-{(1S,3S)-2,2-Dimethyl-3-[3(propan-2-yl)-1,2,4-oxadiazol-5-yl]cyclopropyl}pyridine-2-sulfonamide;

5-[(1S,3S)-3-(5-Cyclopentyl-1,3-oxazol-2-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide;

5-[(1S,3S)-2,2-Dimethyl-3-(5-phenyl- 1,3-thiazol-2-yl)cyclopropyl]pyridine-2-sulfonamide;

5-[(1S,3S)-3-(5-Cyclopentyl-1,3-thiazol-2-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide; 5-{trans-2,2-Dimethyl-3-[5-(2,3,6-trifluorophenyl)-1,2,4-oxadiazol-3-yl]cyclopropyl}pyridine-2-sulfonamide;

5-[trans-3-(5-Cyclopentyl-1,2,4-oxadiazol-3-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide;

5-{trans-3-[3-(3-Fluorophenyl)isoxazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-2-sulfonamide;

5-[trans-3-(1,3-Benzoxazol-2-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide;

5-[trans-2-(3-Phenyl-1,2,4-oxadiazol-5-yl)cyclopropyl]pyridine-2-sulfonamide;

5-[trans-2,2-Dimethyl-3-(3-phenyl-1,2,4-oxadiazol-5-yl)cyclopropyl]pyridine-2-sulfonamide;

5-[trans-3-(1,3-Benzoxazol-2-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide;

5-{trans-2-[3-(3-Fluorophenyl)-1,2,4-oxadiazol-5-yl]cyclopropyl}pyridine-2-sulfonamide;

5-[trans-2-(3-Cyclopentyl-1,2,4-oxadiazol-5-yl)cyclopropyl]pyridine-2-sulfonamide;

5-[trans-3-(5-Cyclohexyl-1,2,4-oxadiazol-3-yl)-2,2-dimethylcyclopropyl]pyridine-2-sulfonamide;

5-(trans-2,2-Dimethyl-3-{5-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-3-yl}cyclopropyl)pyridine-2-sulfonamide;

5-{trans-3-[5-(2,6-Difluorophenyl)-1,2,4-oxadiazol-3-yl]-2,2-dimethylcyclopropyl}pyridine-2-sulfonamide;

5-{trans-3-[5-(3-Fluorophenyl)isoxazol-3-yl]-2,2-dimethylcyclopropyl}pyridine-2-sulfonamide;

2-[trans-3-(1,3-Benzoxazol-2-yl)-2,2-dimethylcyclopropyl]-1,3-thiazole-5-sulfonamide;

2-[trans-3-(3-Cyclobutyl-1,2,4-oxadiazol-5-yl)-2,2-dimethylcyclopropyl]-1,3-thiazole-5-sulfonamide;

2-{trans-3-[3-(5-Fluoropyridin-3-yl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}-1,3-thiazole-5-sulfonamide;

2-[trans-2,2-Dimethyl-3-(3-phenyl-1,2,4-oxadiazol-5-yl)cyclopropyl]-1,3-thiazole-5-sulfonamide;

2-{trans-2,2-Dimethyl-3-[3-(propan-2-yl)-1,2,4-oxadiazol-5-yl]cyclopropyl}-1,3-thiazole-5-sulfonamide;

2-{trans-3-[3-(3,3-Difluorocyclobutyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}-1,3-thiazole-5-sulfonamide;

2-{trans-3-[3-(5-Chloro-2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}-1,3-thiazole-5-sulfonamide;

2-[trans-2-(3-Phenyl-1,2,4-oxadiazol-5-yl)cyclopropyl]-1,3-thiazole-5-sulfonamide;

2-[(1R,3R)-2,2-Dimethyl-3-(3-phenyl-1,2,4-oxadiazol-5-yl)cyclopropyl]-1,3-thiazole-5-sulfonamide;

6-{(1R,3R)-3-[3-(3-Fluorophenyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-3-sulfonamide;

6-[(1R,3R)-3-(3-Cyclopentyl-1,2,4-oxadiazol-5-yl)-2,2-dimethylcyclopropyl]pyridine-3-sulfonamide;

6-[(1R,3R)-2,2-Dimethyl-3-(3-phenyl-1,2,4-oxadiazol-5-yl)cyclopropyl]pyridine-3-sulfonamide

6-{(1R,3R)-3-[3-(5-Chloro-2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-3-sulfonamide;

6-{(1R,3R)-3-[3(2,4-Difluorophenyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-3-sulfonamide;

6-[(1R,3R)-2,2-Dimethyl-3-{3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}cyclopropyl]pyridine-3-sulfonamide;

6-[(1R,3R)-3-(3-Cyclohexyl-1,2,4-oxadiazol-5-yl)-2,2-dimethylcyclopropyl]pyridine-3-sulfonamide;

6- {(1S,3S)-3-[3-(3-Fluorophenyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-3-sulfonamide;

6-[(1S,3S)-2,2-Dimethyl-3-{3-[5-(trifluoromethyl)pyridin-3-yl]-1,2,4-oxadiazol-5-yl}cyclopropyl]pyridine-3-sulfonamide;

6-[(1S,3S)-3-(3-Cyclopentyl-1,2,4-oxadiazol-5-yl)-2,2-dimethylcyclopropyl]pyridine-3-sulfonamide.

6-{(1S,3S)-3-[3-(5-Chloro-2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-3-sulfonamide;

6-{(1S,3S)-3-[3-(2,4-Difluorophenyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-3-sulfonamide;

6-[(1S,3S)-2,2-Dimethyl-3-{3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}cyclopropyl]pyridine-3-sulfonamide;

6-{(1S,3S)-3-[3-(Cyclopropylmethyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-3-sulfonamide;

6-[(1S,3S)-3-(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)-2,2-dimethylcyclopropyl]pyridine-3-sulfonamide;

6-[(1S,3S)-3-(3-tert-Butyl-1,2,4-oxadiazol-5-yl)-2,2-dimethylcyclopropyl]pyridine-3-sulfonamide;

6-[(1S,3S)-2,2-Dimethyl-3-(3-phenyl-1,2,4-oxadiazol-5-yl)cyclopropyl]pyridine-3-sulfonamide;

6-{(1S,3S)-3-[3-(5-Fluoropyridin-3-yl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-3-sulfonamide;

6-{(1S,3S)-3-[3-(3,3-Difluorocyclobutyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-3-sulfonamide;

6-[(1S,3S)-3-(3-Cyclobutyl-1,2,4-oxadiazol-5-yl)-2,2-dimethylcyclopropyl]pyridine-3-sulfonamide;

6-{(1S,3S)-2,2-Dimethyl-3-[3-(propan-2-yl)-1,2,4-oxadiazol-5-yl]cyclopropyl}pyridine-3-sulfonamide;

6-[trans-3-(1,3-Benzoxazol-2-yl)-2,2-dimethylcyclopropyl]pyridine-3-sulfonamide;

6-[trans-2,2-Dimethyl-3-(3-phenyl-1,2,4-oxadiazol-5-yl)cyclopropyl]pyridine-3-sulfonamide;

6-{trans-2,2-Dimethyl-3-[3-(propan-2-yl)-1,2,4-oxadiazol-5-yl]cyclopropyl}pyridine-3-sulfonamide;

6-[trans-3-(3-Cyclobutyl-1,2,4-oxadiazol-5-yl)-2,2-dimethylcyclopropyl]pyridine-3-sulfonamide;

6-{trans-3-[3-(3,3-Difluorocyclobutyl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylcyclopropyl}pyridine-3-sulfonamide;

6-[trans-2-(3-Phenyl-1,2,4-oxadiazol-5-yl)cyclopropyl]pyridine-3-sulfonamide; and

6-[trans-2-(3-Cyclopentyl-1,2,4-oxadiazol-5-yl)cyclopropyl]pyridine-3-sulfonamide.

or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) a compound of claim 1 or a pharmaceutically acceptable salt thereof.

12. The pharmaceutical composition of claim 11 , further comprising a second therapeutic agent selected from the group consisting of acetylcholinesterase inhibitors; NMDA receptor antagonists; antipsychotics; MAO-B inhibitors; and levodopa.

13. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, for use in therapy.